ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » West Virginia » Hematology Oncology

Top Hematology Oncology Prescribers in West Virginia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MUHAMMED KHOKAR MD

Hematology Oncology

3,809

$671K

186
128 are 65+

0%
patients receiving schedule two controlled substances

Avg: 16%

15%
patients receiving schedule three controlled substances

Avg: 12%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 18%

$176
Average prescription price

Avg: $389

HASSAN AMJAD M.D.

Hematology Oncology

3,252

$121K

108
67 are 65+

0%
patients receiving schedule two controlled substances

Avg: 16%

32%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 18%

$37
Average prescription price

Avg: $389

THOMAS PRZYBYSZ MD

Hematology Oncology

2,547

$1.14M

314
271 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 12%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 18%

$448
Average prescription price

Avg: $389

ROWENA GONZALES-CHAMBERS M.D.

Hematology Oncology

2,275

$568K

282
208 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 12%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 18%

$250
Average prescription price

Avg: $389

PAUL BRAGER MD

Hematology Oncology

2,160

$700K

305
241 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 12%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 18%

$324
Average prescription price

Avg: $389

MICHAEL CRAIG M.D.

Hematology Oncology

2,131

$1.21M

145
81 are 65+

35%
patients receiving schedule two controlled substances

Avg: 16%

10%
patients receiving schedule three controlled substances

Avg: 12%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 18%

$570
Average prescription price

Avg: $389

NIK SHAH MD

Hematology Oncology

1,959

$1.1M

298
245 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 12%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 18%

$563
Average prescription price

Avg: $389

DARRELL SAUNDERS MD

Hematology Oncology

1,829

$249K

168
146 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 12%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 18%

$136
Average prescription price

Avg: $389

JOHN AZAR MD, FACP

Hematology Oncology

1,559

$509K

187
158 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

20%
patients receiving schedule three controlled substances

Avg: 12%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$327
Average prescription price

Avg: $389

CRAIG COONLEY MD

Hematology Oncology

1,473

$328K

218
181 are 65+

11%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 18%

$223
Average prescription price

Avg: $389

AHMED KHALID MD

Hematology Oncology

1,463

$678K

215
160 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 12%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 18%

$464
Average prescription price

Avg: $389

ARUN NAGARAJAN MD

Hematology Oncology

1,445

$793K

200
145 are 65+

20%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 12%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 18%

$549
Average prescription price

Avg: $389

ARVINDER BIR M.D.

Hematology Oncology

1,425

$749K

225
187 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 12%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 18%

$526
Average prescription price

Avg: $389

DAMIAN SILBERMINS MD

Hematology Oncology

1,289

$1.42M

154
127 are 65+

20%
patients receiving schedule two controlled substances

Avg: 16%

10%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$1103
Average prescription price

Avg: $389

STEVEN JUBELIRER MD

Hematology Oncology

1,109

$348K

145
108 are 65+

20%
patients receiving schedule two controlled substances

Avg: 16%

18%
patients receiving schedule three controlled substances

Avg: 12%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 18%

$314
Average prescription price

Avg: $389

ARVIND SHAH M.D.

Hematology Oncology

983

$688K

172
126 are 65+

10%
patients receiving schedule two controlled substances

Avg: 16%

16%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 18%

$700
Average prescription price

Avg: $389

CHARLES BEALL M. D.

Hematology Oncology

935

$761K

141
126 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 12%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$814
Average prescription price

Avg: $389

MARIA TIRONA MD

Hematology Oncology

839

$241K

132
90 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

9%
prescriptions for brand name drugs

Avg: 18%

$287
Average prescription price

Avg: $389

NARENDER JOGENPALLY M.D.,

Hematology Oncology

831

$286K

147
112 are 65+

11%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 18%

$344
Average prescription price

Avg: $389

DONALD FLEMING M.D.

Hematology Oncology

820

$669K

137
109 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 18%

$816
Average prescription price

Avg: $389

JAME ABRAHAM M.D.

Hematology Oncology

803

$176K

109
87 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 12%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 18%

$219
Average prescription price

Avg: $389

MATTHEW JONES MD

Hematology Oncology

712

$232K

81
62 are 65+

26%
patients receiving schedule two controlled substances

Avg: 16%

15%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 18%

$326
Average prescription price

Avg: $389

JAMES FRAME MD

Hematology Oncology

674

$323K

163
114 are 65+

0%
patients receiving schedule two controlled substances

Avg: 16%

32%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 18%

$479
Average prescription price

Avg: $389

NI GORSUCH MD

Hematology Oncology

653

$389K

106
79 are 65+

24%
patients receiving schedule two controlled substances

Avg: 16%

0%
patients receiving schedule three controlled substances

Avg: 12%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 18%

$595
Average prescription price

Avg: $389

LOWELL SHINN M.D.

Hematology Oncology

649

$180K

132
111 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 12%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 18%

$277
Average prescription price

Avg: $389

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank